Trials / Unknown
UnknownNCT04872920
Observational Registry on Patients With Endogenous CS to Document Safety and Effectiveness of Ketoconazole.
Prospective, Multi-country, Observational Registry to Collect Clinical Information on Patients With Endogenous Cushing's Syndrome to Assess Drug Utilization Pattern and to Document the Safety and Effectiveness of Ketoconazole.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- HRA Pharma · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-interventional, prospective, multinational, multicentre, observational study, in which data collected are those derived from routine clinical practice via an European registry on CS: ERCUSYN.
Detailed description
The aim is to further document the safety and efficacy of Ketoconazole HRA administered in routine clinical practice in patients with CS. The study operates under real clinical practice conditions, i.e. there is no treatment protocol thus.
Conditions
Timeline
- Start date
- 2018-12-20
- Primary completion
- 2023-03-01
- Completion
- 2024-03-01
- First posted
- 2021-05-05
- Last updated
- 2022-08-30
Locations
6 sites across 4 countries: Croatia, France, Spain, Sweden
Source: ClinicalTrials.gov record NCT04872920. Inclusion in this directory is not an endorsement.